New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned

Novartis AG has unveiled fresh data supporting the efficacy of its Cosentyx (secukinumab) drug in ankylosing spondylitis and psoriatic arthritis along with plans to compare that front-running anti-IL-17A agent against AbbVie Inc.'s anti-TNF competitor Humira (adalimumab) in head-to-head clinical trials.